This study is looking into new ways to treat obstructive sleep apnea (OSA) in people with Down syndrome. OSA is a condition where breathing stops and starts during sleep, which is very common in individuals with Down syndrome and can affect their thinking and quality of life. Current treatments often don't work well or involve surgery. This trial is testing two different approaches: a combination of two medications, atomoxetine and oxybutynin (called "ato-oxy"), or oxygen delivered through a nasal tube. The main goal is to see if these treatments can reduce the number of breathing pauses during sleep after 12 months. You may be able to join if you are 6 years or older and have a diagnosis of Down syndrome.

Study design

This interventional study plans to enroll 200 participants. The phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, obstructive apnea-hypopnea index (oAHI), is measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.